Prostatype Genomics AB (OSTO:PROGEN) EV-to-FCF : -0.45 (As of Apr. 22, 2025)

Prostatype Genomics AB EV-to-FCF Chart

Prostatype Genomics AB Semi-Annual Data
	Jun18	Jun19	Jun20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
EV-to-FCF	Get a 7-Day Free Trial						-1.37	-0.90	-0.70	-	-1.24

Competitive Comparison of Prostatype Genomics AB's EV-to-FCF

For the Diagnostics & Research subindustry, Prostatype Genomics AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prostatype Genomics AB's EV-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Prostatype Genomics AB's EV-to-FCF falls into.

Prostatype Genomics AB EV-to-FCF Calculation

Prostatype Genomics AB's EV-to-FCF for today is calculated as:

Prostatype Genomics AB's current Enterprise Value is kr23.40 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Prostatype Genomics AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was kr-52.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prostatype Genomics AB  (OSTO:PROGEN) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Prostatype Genomics AB's PE Ratio (TTM) for today is calculated as:

Prostatype Genomics AB's share price for today is kr2.15.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Prostatype Genomics AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was kr-1507.727.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Prostatype Genomics AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Prostatype Genomics AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Prostatype Genomics AB Business Description